Entecavir monotherapy versus de novo combination of lamivudine and adefovir for the treatment of naive HBeAg-positive chronic hepatitis B patients with High HBV viral load (the Climber study).

At a glance
Trial Overview
Trial Details
Interventions
Results
- Publications
Authors
Trial Centres
- Investigators
- Centres
Trial History
References

X

Trial Profile

Entecavir monotherapy versus de novo combination of lamivudine and adefovir for the treatment of naive HBeAg-positive chronic hepatitis B patients with High HBV viral load (the Climber study).

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 24 Apr 2016

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Adefovir dipivoxil (Primary) ; Entecavir (Primary) ; Lamivudine
Indications Hepatitis B
Focus Pharmacogenomic; Therapeutic Use
Acronyms Climber

Most Recent Events

21 May 2012 Planned end date 31 Aug 2014 added as reported by Chinese Clinical Trial Register.
10 May 2012 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com